B2M and neoplasm: Moreover, the CRISPR-Cas9 mediated ablation of TCR, beta-2 microglobulin (B2M) and PD-1 concurrently leads to the preparing the CAR-T cells with higher anti-tumor activities than conventional CAR-T cells.